Australia's most trusted
source of pharma news
Thursday, 16 October 2025
Posted 15 October 2025 PM
Global immunology company argenx has signed a strategic partnership with the University of South Australia (UniSA) to advance a pioneering molecule for autoimmune diseases.
It marks the first collaboration of its kind for argenx in Australia and falls under the company's established Immunology Innovation Program which facilitates close work with leading disease biologists around the world to find novel targets for rare and underserved immunological conditions.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.